The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function

BMC Complementary and Alternative Medicine

Volumn 17, Issue 1, 2017, Pages

  Ding, Yuewen ^a,b   Zeng, Lijuan ^a,b   Li, Runfeng ^a   Chen, Qiaoyan ^b   Zhou, Beixian ^a,c   Chen, Qiaolian ^a   Cheng, Pui leng ^d   Yutao, Wang ^a   Zheng, Jingping ^a   Yang, Zifeng ^a,c   Zhang, Fengxue ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Macao)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiviral; Immuno regulation; Influenza virus; Lianhuaqingwen capsule

Indexed keywords

HERBACEOUS AGENT; LIANHUAQINGWEN CAPSULE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIANHUAQINGWEN; NUCLEOCAPSID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; INFLUENZA A (H1N1); INFLUENZA A (H7N9); INFLUENZA VIRUS; MOUSE; NONHUMAN; VIRUS INHIBITION; A-549 CELL LINE; ANIMAL; DRUG EFFECTS; HUMAN; INFLAMMATION; LUNG; METABOLISM; MICROBIAL SENSITIVITY TEST; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PHYTOTHERAPY; VIRUS REPLICATION;

A549 CELLS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; INFLAMMATION; LUNG; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; NF-KAPPA B; NUCLEOCAPSID PROTEINS; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PHYTOTHERAPY; VIRUS REPLICATION;

EID: 85013834593     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-017-1585-7     Document Type: Article

References (33)

1. Klenk HD, Garten W, Matrosovich M. Molecular mechanisms of interspecies transmission and pathogenicity of influenza viruses: Lessons from the 2009 pandemic. Bioessays. 2011;33:180-8.
2. Yang S, Chen Y, Cui D, Yao H, Lou J, Huo Z, Xie G, Yu F, Zheng S, Yang Y, et al. Avian-origin influenza A (H7N9) infection in influenza A (H7N9)-affected areas of China: a serological study. J Infect Dis. 2014;209:265-9.
3. Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5:718-25.
4. Sym D, Patel PN, El-Chaar GM. Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities. Ann Pharmacother. 2009;43:2001-11.
5. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, Lu SH, Yang YD, Fang Q, Shen YZ, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368:2277-85.
6. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14:315-28.
7. Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A. 2007;104:12479-81.
8. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-85.
9. Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, Basler CF, Palese P, Taubenberger JK, Garcia-Sastre A, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature. 2006;443:578-81.
10. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203-7.
11. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella 2nd F, Park DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;164:1896-903.
12. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:Cd008965.
13. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12:240-8.
14. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, Obert C, Seiler P, Keating R, Suzuki Y, Hiramatsu H, et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol. 2010;91:949-59.
15. Zheng BJ, Chan KW, Lin YP, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SS, Lau SK, Woo PC, et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci U S A. 2008;105:8091-6.
16. Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A. 2011;108:12018-23.
17. Hsieh CF, Lo CW, Liu CH, Lin S, Yen HR, Lin TY, Horng JT. Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus. J Ethnopharmacol. 2012;143:57-67.
18. Duan ZP, Jia ZH, Zhang J, Liu S, Chen Y, Liang LC, Zhang CQ, Zhang Z, Sun Y, Zhang SQ, et al. Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial. Chin Med J (Engl). 2011;124:2925-33.
19. Zhong NS, Li YM, Yang ZF, Wang C, Liu YN, Li XW, Shu YL, Wang GF, Gao ZC, Deng GH, et al. Chinese guidelines for diagnosis and treatment of influenza (2011). J Thorac Dis. 2011;3:274-89.
20. Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, Planz O, Ludwig S. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res. 2007;76:38-47.
21. Krah DL. A simplified multiwell plate assay for the measurement of hepatitis a virus infectivity. Biologicals. 1991;19:223-7.
22. Watanabe W, Konno K, Ijichi K, Inoue H, Yokota T, Shigeta S. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents. J Virol Methods. 1994;48:257-65.
23. Kim M, Yim JH, Kim SY, Kim HS, Lee WG, Kim SJ, Kang PS, Lee CK. In vitro inhibition of influenza A virus infection by marine microalga-derived sulfated polysaccharide p-KG03. Antiviral Res. 2012;93:253-9.
24. Serkedjieva J, Hay AJ. In vitro anti-influenza virus activity of a plant preparation from Geranium sanguineum L. Antiviral Res. 1998;37:121-30.
25. Wurzer WJ, Planz O, Ehrhardt C, Giner M, Silberzahn T, Pleschka S, Ludwig S. Caspase 3 activation is essential for efficient influenza virus propagation. Embo j. 2003;22:2717-28.
26. Arimori Y, Nakamura R, Yamada H, Shibata K, Maeda N, Kase T, Yoshikai Y. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res. 2013;99:230-7.
27. Julkunen I, Sareneva T, Pirhonen J, Ronni T, Melen K, Matikainen S. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 2001;12:171-80.
28. Kumar N, Xin ZT, Liang Y, Ly H, Liang Y. NF-kappaB signaling differentially regulates influenza virus RNA synthesis. J Virol. 2008;82:9880-9.
29. Pinto R, Herold S, Cakarova L, Hoegner K, Lohmeyer J, Planz O, Pleschka S. Inhibition of influenza virus-induced NF-kappaB and Raf/MEK/ERK activation can reduce both virus titers and cytokine expression simultaneously in vitro and in vivo. Antiviral Res. 2011;92:45-56.
30. Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, Ruckle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral Res. 2013;99:336-44.
31. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021-5.
32. Ludwig S. Disruption of virus-host cell interactions and cell signaling pathways as an anti-viral approach against influenza virus infections. Biol Chem. 2011;392:837-47.
33. Herold S, Ludwig S, Pleschka S, Wolff T. Apoptosis signaling in influenza virus propagation, innate host defense, and lung injury. J Leukoc Biol. 2012;92:75-82.